Early Outcomes Using TIGR Mesh in Direct-to-Implant Breast Reconstruction

使用TIGR网片进行直接植入式乳房重建的早期结果

阅读:2

Abstract

BACKGROUND: Direct-to-implant (DTI) breast reconstruction often uses soft tissue support to improve outcomes and reduce implant migration. Synthetic meshes, such as TIGR Matrix, have emerged as potential alternatives to biological materials due to lower costs and complication rates. This study reviewed early outcomes using TIGR Matrix in immediate DTI reconstruction. METHODS: A retrospective chart review was conducted on patients who underwent implant-based reconstruction with TIGR Matrix between November 2023 and June 2024 across 2 institutions. Inclusion criteria included DTI reconstruction with at least 6 months of follow-up. Data collected included demographics, oncological and reconstructive details, comorbidities, and postoperative complications. Statistical analysis was performed using MATLAB with t tests and χ(2) tests. RESULTS: Seventy-one patients (109 breasts) met inclusion criteria. The cohort included 42.2% nipple-sparing, 40.4% skin-sparing, and 11.0% Goldilocks mastectomies. The mean patient age was 52 years. The mean time to first postoperative follow-up was 8.3 days. Major complications included 6 hematomas (5.5%), 3 seromas (2.8%), 2 infections (1.8%), and 3 explantations (2.8%). Eleven (10.1%) patients required reoperation due to complications including infection, necrosis, or residual disease. Minor complications (delayed wound healing, eschar) were observed in 17.4% of breasts. The overall complication rate excluding minor events was 12.8%. CONCLUSIONS: TIGR Matrix demonstrates an acceptable early complication profile in DTI breast reconstruction and may serve as a cost-effective alternative to acellular dermal matrices. Additional studies are needed to assess long-term outcomes and comparative effectiveness.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。